中国临床药理学杂志2024，Vol.40Issue(20)：3047-3050,4.DOI:10.13699/j.cnki.1001-6821.2024.20.028
新型双重内皮素受体拮抗药——Aprocitentan
Novel dual endothelin-receptor antagonist—-—Aprocitentan
摘要
Abstract
Aprocitentan is a dual endothelin receptor antagonist.Based on the effective evidence of Ⅲ phases of clinical trials,the drug was approved for marketing by the U.S.Food and Drug Administration on March 19,2024 for the treatment of refractory hypertension.At present,multiple clinical studies have confirmed that Aprocitentan has excellent antihypertensive effects and good tolerability.This article reviews the pharmacological effects,preclinical.关键词
Aprocitentan/内皮素受体拮抗药/难治性高血压Key words
Aprocitentan/endothelin receptor antagonist/resistant hypertension分类
医药卫生引用本文复制引用
卫愿奎,朱宝强,张明名,杨诗语,龙恩武..新型双重内皮素受体拮抗药——Aprocitentan[J].中国临床药理学杂志,2024,40(20):3047-3050,4.基金项目
个体化药物治疗四川省重点实验室课题资助项目(2017LY16) （2017LY16）
